Literature DB >> 7622258

Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration.

B L Røder1, N Frimodt-Møller, F Espersen, S N Rasmussen.   

Abstract

The pharmacokinetics of dicloxacillin and flucloxacillin were studied in 12 healthy volunteers after oral administration. The participants received a single dose of either dicloxacillin (0.5 g, 0.75 g or 1.0 g) or flucloxacillin (0.75 g) in a cross-over fashion. Antibiotic concentrations were determined in serum and urine by bioassay and followed for 8 and 24 h, respectively. The three dicloxacillin dosages showed no significant differences for the serum elimination half-lives (t1/2 beta, median: 72 min). Comparing 0.75 g flucloxacillin with the same dose of dicloxacillin, no significant differences between the values of Cmax, t1/2 beta and AUC were found. Protein binding as determined by ultrafiltration in pooled serum was 94.7-96.2% for flucloxacillin and 96.4-97.2% for dicloxacillin. The serum bactericidal titers were similar for the two drugs. In conclusion, dicloxacillin and flucloxacillin showed similar pharmacokinetic behavior after 0.75 g doses in human volunteers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622258     DOI: 10.1007/bf01833876

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  DICLOXACILLIN, A NEW ANTIBIOTIC: CLINICAL STUDIES AND LABORATORY COMPARISONS WITH OXACILLIN AND CLOXACILLIN.

Authors:  J V BENNETT; C F GRAVENKEMPER; J L BRODIE; W M KIRBY
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

2.  Flucloxacillin: a new semisynthetic isoxazolyl penicillin.

Authors:  G P Bodey; C Vallejos; D Stewart
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

3.  Mechanisms responsible for the blood level differences of isoxazolyl penicillins: oxacillin, cloxacillin, and dicloxacillin.

Authors:  J E Rosenblatt; A C Kind; J L Brodie; W M Kirby
Journal:  Arch Intern Med       Date:  1968-04

4.  Serum levels, urinary recovery, and safety of dicloxacillin, a new semisynthetic penicillin, in normal volunteers.

Authors:  E A De Felice
Journal:  J Clin Pharmacol J New Drugs       Date:  1967 Sep-Oct

5.  Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis.

Authors:  E H Nauta; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

6.  Clinical, laboratory, and pharmacological studies of dicloxacillin.

Authors:  C F Hammerstrom; F Cox; M C McHenry; E L Quinn
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

7.  Single-dose pharmacokinetics of dicloxacillin in healthy subjects of young and old age.

Authors:  S Löfgren; G Bucht; B Hermansson; S E Holm; B Winblad; S R Norrby
Journal:  Scand J Infect Dis       Date:  1986

8.  Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects.

Authors:  E H Nauta; H Mattie
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

9.  Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin.

Authors:  R Sutherland; E A Croydon; G N Rolinson
Journal:  Br Med J       Date:  1970-11-21

10.  Plasma protein binding of dicloxacillin: effects of age and diseases.

Authors:  G M Pacifici; A Viani; G Taddeucci-Brunelli; G Rizzo; M Carrai
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-11
View more
  16 in total

1.  Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

Authors:  Stefan Russmann; James A Kaye; Susan S Jick; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis.

Authors:  Sabah El-Ghaiesh; Manal M Monshi; Paul Whitaker; Rosalind Jenkins; Xiaoli Meng; John Farrell; Ayman Elsheikh; Daniel Peckham; Neil French; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2012-02-27       Impact factor: 4.030

3.  Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.

Authors:  Ashley R Maiuri; Bronlyn Wassink; Jonathan D Turkus; Anna B Breier; Theresa Lansdell; Gurpreet Kaur; Sarah L Hession; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2017-07-07       Impact factor: 4.030

4.  Synergistic antibacterial effects of herbal extracts and antibiotics on methicillin-resistant Staphylococcus aureus: A computational and experimental study.

Authors:  Chiu-Fai Kuok; Sai-On Hoi; Chi-Fai Hoi; Chi-Hong Chan; Io-Hong Fong; Cheong-Kei Ngok; Li-Rong Meng; Pedro Fong
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

5.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia.

Authors:  Paul Ken Leong Chin; Philip George Drennan; Sharon Jane Gardiner; Mei Zhang; Simon Charles Dalton; Stephen Thomas Chambers; Evan James Begg
Journal:  Br J Clin Pharmacol       Date:  2018-07-20       Impact factor: 4.335

7.  Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.

Authors:  Anne Sandberg; Jonas H R Hessler; Robert L Skov; Jens Blom; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Microdialysis as a tool to determine the local tissue concentration of dicloxacillin in man.

Authors:  Kristian Kraft Hansen; Flemming Nielsen; Tore Bjerregaard Stage; Uffe Jørgensen; Ole Skov; Lasse E Rasmussen
Journal:  Br J Clin Pharmacol       Date:  2017-12-07       Impact factor: 4.335

9.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Authors:  Tore Bjerregaard Stage; Magnus Graff; Susan Wong; Louise Ladebo Rasmussen; Flemming Nielsen; Anton Pottegård; Kim Brøsen; Deanna L Kroetz; S Cyrus Khojasteh; Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

10.  PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2002-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.